Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME.

Oncologist. 2018 Jul 17. pii: theoncologist.2018-0117. doi: 10.1634/theoncologist.2018-0117. [Epub ahead of print]

PMID:
30018131
2.

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM.

Oncologist. 2018 Jun 4. pii: theoncologist.2018-0143. doi: 10.1634/theoncologist.2018-0143. [Epub ahead of print]

PMID:
29866946
3.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.

PMID:
29791286
4.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.

Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ.

Mol Cancer Res. 2018 May;16(5):805-812. doi: 10.1158/1541-7786.MCR-17-0735. Epub 2018 Mar 9.

PMID:
29523759
5.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6. Review.

PMID:
29508762
6.

Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 319(2) (2012) 173-181].

Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, Sarkar FH.

Cancer Lett. 2018 Feb 1;414:313. doi: 10.1016/j.canlet.2017.11.030. No abstract available.

7.

The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

Tesfaye AA, Kamgar M, Azmi A, Philip PA.

Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148. doi: 10.1080/14737140.2018.1417844. Epub 2017 Dec 19.

8.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

9.

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.

Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL.

Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.

10.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

11.

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW.

Oncology. 2018;94(1):39-46. doi: 10.1159/000480295. Epub 2017 Oct 18.

12.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2017 Jun 22:0. doi: 10.1080/21541248.2017.1329694. [Epub ahead of print]

PMID:
28641032
13.

Evolving standards of care for resected pancreatic cancer.

Weinberg BA, Philip PA, Salem ME.

Clin Adv Hematol Oncol. 2017 Feb;15(2):141-150. Review.

PMID:
28398285
14.

Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study.

Separovic D, Shields AF, Philip PA, Bielawski J, Bielawska A, Pierce JS, Tarca AL.

Anticancer Res. 2017 Mar;37(3):1213-1218.

PMID:
28314284
15.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

16.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS.

JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383.

17.

An update on the multimodality of localized rectal cancer.

Artac M, Korkmaz L, El-Rayes B, Philip PA.

Crit Rev Oncol Hematol. 2016 Dec;108:23-32. doi: 10.1016/j.critrevonc.2016.10.004. Epub 2016 Oct 26. Review.

PMID:
27931837
18.

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA.

Ann Oncol. 2016 Dec;27(12):2196-2203. doi: 10.1093/annonc/mdw423. Epub 2016 Oct 20.

PMID:
27765757
19.

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.

Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA.

J Clin Med. 2016 Jun 16;5(6). pii: E59. doi: 10.3390/jcm5060059. Review.

20.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D.

J Clin Oncol. 2016 Aug 10;34(23):2784-96. doi: 10.1200/JCO.2016.67.1412. Epub 2016 May 31. Review.

21.

Targeting macrophages to treat pancreatic cancer.

Philip PA.

Lancet Oncol. 2016 May;17(5):552-3. doi: 10.1016/S1470-2045(16)00151-0. Epub 2016 Apr 4. No abstract available. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223.

PMID:
27055730
22.

F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS.

Semin Cancer Biol. 2016 Feb;36:95-104. doi: 10.1016/j.semcancer.2016.01.002. Epub 2016 Jan 21. Review.

23.

The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.

Suresh R, Ali S, Ahmad A, Philip PA, Sarkar FH.

Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4. Review.

PMID:
26703799
24.

Systemic Therapy of Pancreatic Cancer: Better Science, Faster Progress.

Philip PA.

Oncology (Williston Park). 2015 Nov;29(11):821, 826. No abstract available.

25.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

26.

Interprofessionalism between physicians and nurses: moving forward.

Lui JK, Philbin M, Lau S, Philip PA, Yazdani M, Hatem D.

Int J Nurs Stud. 2015 Dec;52(12):1785-8. doi: 10.1016/j.ijnurstu.2015.09.011. Epub 2015 Sep 28. No abstract available.

PMID:
26442700
27.

Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.

Philip PA, Lutz MP.

Pancreas. 2015 Oct;44(7):1046-52. doi: 10.1097/MPA.0000000000000389. Review.

PMID:
26355547
28.

Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells.

Ali S, Suresh R, Banerjee S, Bao B, Xu Z, Wilson J, Philip PA, Apte M, Sarkar FH.

Am J Cancer Res. 2015 Feb 15;5(3):1251-64. eCollection 2015.

29.

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS.

World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450. Review.

30.

PET scans as a predictive marker of survival in advanced colorectal cancer.

Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA.

Clin Colorectal Cancer. 2015 Mar;14(1):35-40. doi: 10.1016/j.clcc.2014.10.001. Epub 2014 Oct 23.

31.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD.

Cancer. 2014 Oct 1;120(19):2980-5. doi: 10.1002/cncr.28744. Epub 2014 Jul 16.

32.

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.

Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J.

Clin Cancer Res. 2014 Aug 15;20(16):4176-85. doi: 10.1158/1078-0432.CCR-13-2024. Epub 2014 Jun 9.

33.

Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling.

Ali S, Ahmad A, Aboukameel A, Ahmed A, Bao B, Banerjee S, Philip PA, Sarkar FH.

Cancer Lett. 2014 Aug 28;351(1):134-42. doi: 10.1016/j.canlet.2014.05.013. Epub 2014 May 16.

34.

Clinical implication of microRNAs in molecular pathology.

Sethi S, Ali S, Kong D, Philip PA, Sarkar FH.

Clin Lab Med. 2013 Dec;33(4):773-86. doi: 10.1016/j.cll.2013.08.001. Epub 2013 Oct 9. Review.

PMID:
24267185
35.

Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA.

Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA, Li Y.

Am J Cancer Res. 2013 Nov 1;3(5):465-77. eCollection 2013.

36.

Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization.

Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA.

ISRN Oncol. 2013 Sep 15;2013:538376. doi: 10.1155/2013/538376. eCollection 2013.

37.

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-AviƱa J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.

J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.

PMID:
23980084
38.

Clinical advances in molecular biomarkers for cancer diagnosis and therapy.

Sethi S, Ali S, Philip PA, Sarkar FH.

Int J Mol Sci. 2013 Jul 16;14(7):14771-84. doi: 10.3390/ijms140714771. Review.

39.

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA.

Eur J Cancer. 2013 Aug;49(12):2633-42. doi: 10.1016/j.ejca.2013.04.002. Epub 2013 Apr 30.

PMID:
23642329
40.

Systems biology approaches to pancreatic cancer detection, prevention and treatment.

Alian OM, Philip PA, Sarkar FH, Azmi AS.

Curr Pharm Des. 2014;20(1):73-80. Review.

PMID:
23530496
41.

First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA.

Clin Cancer Res. 2013 Feb 15;19(4):920-8. doi: 10.1158/1078-0432.CCR-12-2616. Epub 2013 Jan 29.

42.

Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.

Strosberg JR, Fisher GA, Benson AB, Malin JL; GEPNET Treatment Consensus Panel, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM.

Pancreas. 2013 Apr;42(3):397-404. doi: 10.1097/MPA.0b013e31826d3a17.

PMID:
23211372
43.

A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.

Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, Papageorgio C, Auber ML, Kaleta R, McHenry MB, Trifan OC, Philip PA.

Gastrointest Cancer Res. 2012 Sep;5(5):155-60.

44.

Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.

Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM.

Gastroenterology. 2013 Feb;144(2):447-56. doi: 10.1053/j.gastro.2012.10.036. Epub 2012 Oct 23.

45.

Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101.

Qazi AM, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, Weaver DW, Gruber SA, Batchu RB.

Surgery. 2012 Oct;152(4):704-11; discussion 711-3. doi: 10.1016/j.surg.2012.07.020. Epub 2012 Sep 1.

PMID:
22943841
46.

MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer.

Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA.

Br J Cancer. 2012 Oct 9;107(8):1354-60. doi: 10.1038/bjc.2012.383. Epub 2012 Aug 28.

47.

Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.

Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, Sarkar F.

Anticancer Res. 2012 Aug;32(8):3559-63.

48.

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T.

Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11.

49.

The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis.

Ali AS, Ahmad A, Ali S, Bao B, Philip PA, Sarkar FH.

J Cell Physiol. 2013 Jan;228(1):36-42. doi: 10.1002/jcp.24127. Review.

50.

Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.

Soubani O, Ali AS, Logna F, Ali S, Philip PA, Sarkar FH.

Carcinogenesis. 2012 Aug;33(8):1563-71. doi: 10.1093/carcin/bgs189. Epub 2012 May 27.

Supplemental Content

Loading ...
Support Center